Anti-Rheumatic Drugs - Jamaica | Statista Market Forecast

The Anti-Rheumatic Drugs market in Jamaica is expected to witness a significant revenue growth in the coming years.
By 2024, the projected revenue is estimated to reach US$2.31m.
Furthermore, it is anticipated that the market will experience a steady annual growth rate of 0.30% between 2024 and 2029.
This growth trajectory will result in a market volume of US$2.34m by 2029.
When comparing the global market, it is noteworthy that United States is expected to generate the highest revenue in the Anti-Rheumatic Drugs market.
In 2024 alone, the revenue United States is projected to reach a staggering US$34.70bn.
This indicates the dominance of the American market in this particular market.
Jamaica's anti-rheumatic drug market is experiencing an increase in demand due to the rising prevalence of rheumatic diseases in the country.

Definition:
The market Anti-Rheumatic Drugs includes medication for the treatment of the inflammatory disease rheumatism. Due to the high prevalence of rheumatism and the large size of the market, this section of immune diseases is treated as a separate market. Both steroidal and non-steroidal anti-rheumatics are included. Disease-modifying rheumatic drugs (DMARDs), such as tumor necrosis factor inhibitors (a type of biologic DMARD), are particularly important in terms of commerciality.

Additional information:
Market values represent the revenues generated by manufacture prices paid to primary vendors, either directly or through distribution channels (excluding VAT). Reported market revenues include spending by consumers (B2C), companies (B2B), and governments (B2G).

Company examples: AbbVie, Johnson & Johnson, Pfizer, Amgen, Roche

Drugs to treat rheumatism
Steroidal (corticosteroids) and non-steroidal anti-rheumatics
Disease-modifying antirheumatic drugs (DMARDs)
Tumor necrosis factor (TNF) inhibitors

Drugs to treat other autoimmune diseases (such as multiple sclerosis or psoriasis)
Analgetics for general use (such as paracetamol)
Treatment of osteoarthritis

The Anti-Rheumatic Drugs market in Jamaica has been steadily growing over the past few years, with a number of factors contributing to this growth.

Customer preferences: Jamaican customers have shown a preference for anti-rheumatic drugs that are affordable and effective. With limited access to healthcare, many Jamaicans rely on over-the-counter medication to manage their symptoms. As a result, there is a high demand for anti-rheumatic drugs that are both affordable and accessible.

Trends in the market: One of the main trends in the Anti-Rheumatic Drugs market in Jamaica is the increasing availability of generic drugs. This has allowed more Jamaicans to access the medication they need at a lower cost. Another trend is the growing awareness of the benefits of early diagnosis and treatment. As more Jamaicans become aware of the importance of managing their symptoms, the demand for anti-rheumatic drugs is likely to continue to grow.

Local special circumstances: Jamaica's healthcare system is underfunded and understaffed, which has led to a lack of access to healthcare for many Jamaicans. This has led to a reliance on over-the-counter medication and a preference for affordable anti-rheumatic drugs. Additionally, Jamaica has a high prevalence of rheumatoid arthritis, which has contributed to the demand for anti-rheumatic drugs.

Underlying macroeconomic factors: Jamaica's economy has been growing steadily over the past few years, which has led to an increase in disposable income for many Jamaicans. This has allowed more Jamaicans to afford the medication they need to manage their symptoms. Additionally, Jamaica has a growing aging population, which has contributed to the demand for anti-rheumatic drugs. As the population continues to age, the demand for these drugs is likely to continue to grow.

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.

This report presents a comprehensive analysis and additional information on the Health market, in a PDF format.

The pharmaceutical industry is responsible for the research, development, production, and distribution of medications. The market has experienced significant growth during the past two decades, and pharma revenues worldwide totaled 1.48 trillion U.S. dollars in 2022.